CN105641171A - Medicine for treating lung cancer by combination of Chinese traditional medicine and western medicine and preparation method thereof - Google Patents
Medicine for treating lung cancer by combination of Chinese traditional medicine and western medicine and preparation method thereof Download PDFInfo
- Publication number
- CN105641171A CN105641171A CN201610170936.8A CN201610170936A CN105641171A CN 105641171 A CN105641171 A CN 105641171A CN 201610170936 A CN201610170936 A CN 201610170936A CN 105641171 A CN105641171 A CN 105641171A
- Authority
- CN
- China
- Prior art keywords
- parts
- medicine
- medulla
- chinese traditional
- lung cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 62
- 206010058467 Lung neoplasm malignant Diseases 0.000 title claims abstract description 27
- 201000005202 lung cancer Diseases 0.000 title claims abstract description 14
- 208000020816 lung neoplasm Diseases 0.000 title claims abstract description 14
- 229940079593 drug Drugs 0.000 title claims description 10
- 238000002360 preparation method Methods 0.000 title abstract description 6
- 239000009636 Huang Qi Substances 0.000 claims abstract description 13
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims abstract description 13
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims abstract description 13
- 229960003668 docetaxel Drugs 0.000 claims abstract description 13
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims abstract description 13
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims abstract description 13
- 229960005277 gemcitabine Drugs 0.000 claims abstract description 13
- 239000002994 raw material Substances 0.000 claims abstract description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- 241001501111 Erycibe Species 0.000 claims description 17
- 241000628997 Flos Species 0.000 claims description 17
- 239000000341 volatile oil Substances 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 229940084651 iressa Drugs 0.000 claims description 12
- 239000012153 distilled water Substances 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 10
- 229920000858 Cyclodextrin Polymers 0.000 claims description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 5
- 239000012141 concentrate Substances 0.000 claims description 5
- 230000006837 decompression Effects 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 238000002481 ethanol extraction Methods 0.000 claims description 5
- 239000000284 extract Substances 0.000 claims description 5
- -1 hydroxypropyl Chemical group 0.000 claims description 5
- 238000007654 immersion Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 238000004064 recycling Methods 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- 230000000694 effects Effects 0.000 abstract description 7
- 239000004615 ingredient Substances 0.000 abstract description 2
- 230000007721 medicinal effect Effects 0.000 abstract description 2
- 241001375490 Adenosma Species 0.000 abstract 1
- 241000722824 Ardisia crenata Species 0.000 abstract 1
- 241001113925 Buddleja Species 0.000 abstract 1
- 241001438908 Erycibe obtusifolia Species 0.000 abstract 1
- 235000002384 Malva verticillata Nutrition 0.000 abstract 1
- 240000003065 Malva verticillata Species 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 229960002584 gefitinib Drugs 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000000391 smoking effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 208000000616 Hemoptysis Diseases 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010040007 Sense of oppression Diseases 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000003500 flue dust Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 238000009936 smoking Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/40—Cornaceae (Dogwood family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/56—Loganiaceae (Logania family), e.g. trumpetflower or pinkroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/67—Piperaceae (Pepper family), e.g. Jamaican pepper or kava
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses medicine for treating lung cancer by combination of Chinese traditional medicine and western medicine and a preparation method thereof. The medicine is prepared from the following raw materials in parts by weight: 55 to 80 parts of pale butterflybush flower, 41 to 59 parts of erycibe obtusifolia benth, 31 to 49 parts of indian adenosma herb, 22 to 43 parts of cluster mallow fruit, 20 to 34 parts of medulla stachyuri, 15 to 28 parts of stenoloma chusana, 10 to 18 parts of ardisia crenata, 5 to 13 parts of Bibo, 2 to 11 parts of roasted radix astragali, 0.1 to 0.6 part of gefitinib, 0.5 to 1.3 parts of gemcitabine and 0.6 to 1.8 parts of docetaxel. The treatment effect of the Chinese traditional medicine and western medicine combination medicine on lung cancer treatment is better than that of ordinary pure Chinese traditional medicine and western medicine; the efficacies of the Chinese traditional medicine ingredients and the western medicine can be improved to the greatest degree; the complementation and promotion effects are exerted; the medicinal effect is improved.
Description
Technical field
The present invention relates to the medicine of a kind of Lung Cancer with Integrated Traditonal Chinese Westren Medicine.
Background technology
Pulmonary carcinoma is that M & M increases the soonest, one of malignant tumor maximum to population health and life threat. The many countries of immediate and mid-term all report that the M & M of pulmonary carcinoma all substantially increases, and male lung cancer M & M all accounts for first of all malignant tumor. So far still not exclusively clearly, great mass of data shows the cause of disease of pulmonary carcinoma, and long-term a large amount of smokings have very close relationship with pulmonary carcinoma. Existing research proves: the probability that long-term a large amount of smokers suffer from pulmonary carcinoma is 10��20 times of non-smoker, and the age starting smoking is more little, and the probability suffering from pulmonary carcinoma is more high. Additionally, smoking not only directly affects my healthy, also the health of surrounding population is produced harmful effect, cause that involuntary smoker's pulmonary carcinoma prevalence substantially increases. The sickness rate of urbanite's pulmonary carcinoma is higher than rural area, and this is likely to relevant containing carcinogen with urban atmospheric pollution and flue dust.
The therapeutic modality of current pulmonary carcinoma has excision or chemicotherapy etc. Aforesaid way is relatively big to the physical impairment of patient, sometimes even can accelerate the death of patient. Simultaneously for Patients with Advanced Lung Cancer, above-mentioned therapeutic modality is unsuitable for.
Summary of the invention
The technical problem to be solved is: provide the pharmaceutical preparation of the Lung Cancer with Integrated Traditonal Chinese Westren Medicine that a kind of cure rate is high.
For solving above-mentioned technical problem, the technical solution used in the present invention is:
The medicine of Lung Cancer with Integrated Traditonal Chinese Westren Medicine provided by the invention, it is characterised in that be made up of the raw material of following weight portion: Flos Buddlejae 55-80 part, Caulis Erycibes 41-59 part, Herba Adenosmae 31-49 part, Fructus Malvae 22-43 part, Medulla Stachyuri (Medulla Helwingiae) 20-34 part, Stenoloma chusana 15-28 part, Radix Ardisiae Crenatae 10-18 part, BIBO 5-13 part, Radix Astragali Preparata 2-11 part, Iressa 0.1-0.6 part, gemcitabine 0.5-1.3 part, docetaxel 0.6-1.8 part.
Preferably, medicine provided by the invention is made up of the raw material of Chinese medicine of following weight portion: Flos Buddlejae 63 parts, Caulis Erycibes 52 parts, Herba Adenosmae 40 parts, Fructus Malvae 32 parts, Medulla Stachyuri (Medulla Helwingiae) 26 parts, Stenoloma chusana 20 parts, Radix Ardisiae Crenatae 14 parts, BIBO 8 parts, Radix Astragali Preparata 5 parts, Iressa 0.3 part, gemcitabine 0.9 part, docetaxel 1.2 parts.
The present invention also provides for a kind of method preparing medicine, comprises the following steps:
(1) take Flos Buddlejae, Caulis Erycibes, Herba Adenosmae and Fructus Malvae and add distilled water immersion 5-9 hour, extract volatile oil with volatile oil extractor, dry acquirement volatile oil with anhydrous magnesium sulfate, then use hydroxypropyl��-cyclodextrin inclusion, preparing clathrate, clathrate and medicinal residues are standby;
(2) take Medulla Stachyuri (Medulla Helwingiae), Stenoloma chusana, Radix Ardisiae Crenatae, add 75% ethanol extraction 3-6 time, each 1-3 hour, merge medicinal liquid, stand 24 hours, standby;
(3) after taking the medicinal residues mixing of BIBO, Radix Astragali Preparata and step (1), then the ethanol adding the water of gross weight 5-6 times and the 70% of 0.3-1 times decocts 1.5-3h, double, merges the extracting solution of twice;
(4) taking the supernatant of step (2), (3), decompression recycling ethanol, be concentrated into 55 DEG C-65 DEG C, density is the extractum of 1.01-1.04, and concentrate drying makes powder;
(5) by the clathrate of step (1), the powder of (4) and Iressa, gemcitabine, docetaxel mix homogeneously.
Preferably, in step (1), the weight of distilled water is 3-6 times of Flos Buddlejae, Caulis Erycibes, Herba Adenosmae and Fructus Malvae gross weight, and temperature is 40-60 degree Celsius.
Preferably, the medicine of step (5) loads capsule, and the nt wt net weight of built-in medicine is 1 gram, and the using method of medicine is: oral, twice on the one, one time one.
Beneficial effects of the present invention:
The present invention provides the Drug therapy pulmonary carcinoma of the combination of Chinese and Western medicine than the general simple traditional Chinese medical science and western medical treatment effect more preferably, it is possible to improves effect of Chinese medicine ingredients and Western medicine, performance complementation and castering action to greatest extent, improves medicinal effects.
Chinese medicine and its effect of Western medicine component all act on lung, the heart, have detumescence, lung moistening, reduce phlegm, cough-relieving effect, and cancerous cell has very strong inhibitory action. While anticancer, also promoting body constitution, invigorating the spleen and replenishing QI, nourishing blood to tranquillize the mind, to improve patient's resistance, reaches the effect for the treatment of both the principal and secondary aspects of a disease.
Chinese medicine used by the present invention, collocation rationally, can alleviate the clinical symptoms of patients with lung cancer, alleviates the toxicity of Radiotherapy chemotherapy, improves treatment rate, extends life span.
Detailed description of the invention
Embodiment 1
The medicine of the Lung Cancer with Integrated Traditonal Chinese Westren Medicine that the present embodiment provides, is made up of the raw material of following weight: Flos Buddlejae 63 parts, Caulis Erycibes 52 parts, Herba Adenosmae 40 parts, Fructus Malvae 32 parts, Medulla Stachyuri (Medulla Helwingiae) 26 parts, Stenoloma chusana 20 parts, Radix Ardisiae Crenatae 14 parts, BIBO 8 parts, Radix Astragali Preparata 5 parts, Iressa 0.3 part, gemcitabine 0.9 part, docetaxel 1.2 parts.
In preparation, the method for medicine, comprises the following steps:
(1) take Flos Buddlejae, Caulis Erycibes, Herba Adenosmae and Fructus Malvae and add distilled water immersion 7 hours, extract volatile oil with volatile oil extractor, dry acquirement volatile oil with anhydrous magnesium sulfate, then use hydroxypropyl��-cyclodextrin inclusion, preparing clathrate, clathrate and medicinal residues are standby;
(2) take Medulla Stachyuri (Medulla Helwingiae), Stenoloma chusana, Radix Ardisiae Crenatae, add 75% ethanol extraction 5 times, each 2 hours, merge medicinal liquid, stand 24 hours, standby;
(3) after taking the medicinal residues mixing of BIBO, Radix Astragali Preparata and step (1), then the ethanol adding the water of gross weight 6 times and the 70% of 0.6 times decocts 2h, double, merges the extracting solution of twice;
(4) taking the supernatant of step (2), (3), decompression recycling ethanol, be concentrated into 60 DEG C, density is the extractum of 1.03, and concentrate drying makes powder;
(5) by the clathrate of step (1), the powder of (4) and Iressa, gemcitabine, docetaxel mix homogeneously.
In step (1), the weight of distilled water is 4 times of Flos Buddlejae, Caulis Erycibes, Herba Adenosmae and Fructus Malvae gross weight, and temperature is 50 degrees Celsius.
The medicine of step (5) is loaded capsule, and the nt wt net weight of built-in medicine is 1 gram, and the using method of medicine is: oral, twice on the one, one time one.
Embodiment 2
The medicine of the Lung Cancer with Integrated Traditonal Chinese Westren Medicine that the present embodiment provides, is made up of the raw material of following weight: Flos Buddlejae 80 parts, Caulis Erycibes 59 parts, Herba Adenosmae 49 parts, Fructus Malvae 43 parts, Medulla Stachyuri (Medulla Helwingiae) 34 parts, Stenoloma chusana 28 parts, Radix Ardisiae Crenatae 18 parts, BIBO 13 parts, Radix Astragali Preparata 11 parts, Iressa 0.6 part, gemcitabine 1.3 parts, docetaxel 1.8 parts.
In preparation, the method for medicine, comprises the following steps:
(1) take Flos Buddlejae, Caulis Erycibes, Herba Adenosmae and Fructus Malvae and add distilled water immersion 9 hours, extract volatile oil with volatile oil extractor, dry acquirement volatile oil with anhydrous magnesium sulfate, then use hydroxypropyl��-cyclodextrin inclusion, preparing clathrate, clathrate and medicinal residues are standby;
(2) take Medulla Stachyuri (Medulla Helwingiae), Stenoloma chusana, Radix Ardisiae Crenatae, add 75% ethanol extraction 6 times, each 3 hours, merge medicinal liquid, stand 24 hours, standby;
(3) after taking the medicinal residues mixing of BIBO, Radix Astragali Preparata and step (1), then the ethanol adding the water of gross weight 6 times and the 70% of 1 times decocts 3h, double, merges the extracting solution of twice;
(4) taking the supernatant of step (2), (3), decompression recycling ethanol, be concentrated into 65 DEG C, density is the extractum of 1.04, and concentrate drying makes powder;
(5) by the clathrate of step (1), the powder of (4) and Iressa, gemcitabine, docetaxel mix homogeneously.
In step (1), the weight of distilled water is 6 times of Flos Buddlejae, Caulis Erycibes, Herba Adenosmae and Fructus Malvae gross weight, and temperature is 60 degrees Celsius.
The medicine of step (5) loads capsule, and the nt wt net weight of built-in medicine is 1 gram, and the using method of medicine is: oral, twice on the one, one time one.
Embodiment 3
The medicine of the Lung Cancer with Integrated Traditonal Chinese Westren Medicine that the present embodiment provides, is made up of the raw material of following weight: Flos Buddlejae 55 parts, Caulis Erycibes 41 parts, Herba Adenosmae 31 parts, Fructus Malvae 22 parts, Medulla Stachyuri (Medulla Helwingiae) 20 parts, Stenoloma chusana 15 parts, Radix Ardisiae Crenatae 10 parts, BIBO 5 parts, Radix Astragali Preparata 2 parts, Iressa 0.1 part, gemcitabine 0.5 part, docetaxel 0.6 part.
In preparation, the method for medicine, comprises the following steps:
(1) take Flos Buddlejae, Caulis Erycibes, Herba Adenosmae and Fructus Malvae and add distilled water immersion 5 hours, extract volatile oil with volatile oil extractor, dry acquirement volatile oil with anhydrous magnesium sulfate, then use hydroxypropyl��-cyclodextrin inclusion, preparing clathrate, clathrate and medicinal residues are standby;
(2) take Medulla Stachyuri (Medulla Helwingiae), Stenoloma chusana, Radix Ardisiae Crenatae, add 75% ethanol extraction 3 times, each 1 hour, merge medicinal liquid, stand 24 hours, standby;
(3) after taking the medicinal residues mixing of BIBO, Radix Astragali Preparata and step (1), then the ethanol adding the water of gross weight 5 times and the 70% of 0.3 times decocts 1.5h, double, merges the extracting solution of twice;
(4) taking the supernatant of step (2), (3), decompression recycling ethanol, be concentrated into 55 DEG C DEG C, density is the extractum of 1.01, and concentrate drying makes powder;
(5) by the clathrate of step (1), the powder of (4) and Iressa, gemcitabine, docetaxel mix homogeneously.
In step (1), the weight of distilled water is 3 times of Flos Buddlejae, Caulis Erycibes, Herba Adenosmae and Fructus Malvae gross weight, and temperature is 40-60 degree Celsius.
The medicine of step (5) loads capsule, and the nt wt net weight of built-in medicine is 1 gram, and the using method of medicine is: oral, twice on the one, one time one.
Clinical data:
1, physical data
Patients with Non-small-cell Lung 200 example is carried out clinical observation, and the age of patient is 30-75 year, 52 years old mean age.Wherein patients with terminal 120 example, early stage patient 80 example.
2, diagnostic criteria
Western medicine diagnose standard: Diagnosis of Non-Small Cell Lung standard adopts specified standard in " the China's common cancer diagnosis and treatment specification " that Department of Medical Administration of Ministry of Health of the People's Republic of China writes.
3, Therapeutic Method
Adopt medicine of the present invention, oral, twice on the one, one time one.
4, efficacy assessment standard:
Complete incidence graph (CR): all visible focuses are wholly absent, and at least maintain more than 4 weeks;
Partial rcsponse (PR): the product in longest diameter of tumor and maximum perpendicular footpath reduces more than 50%, is in progress without other focuses, occurs without any new focus;
Stable disease unchanged (SD): the product in longest diameter of tumor and maximum perpendicular footpath reduces less than 50%, or increase less than 25%, occur without any new focus;
Progress (PD): the product in longest diameter of tumor and maximum perpendicular footpath increases more than 25%; CR+PR is total effective rate.
5, therapeutic effect: complete incidence graph: 161 examples, partial rcsponse: 30 examples, stable disease is unchanged: 9 examples, PD:0 example. Total effective rate is 100%.
Model case
Case 1: model, female, 54 years old. Patient is diagnosed as pulmonary carcinoma through CT examination, adopts the medicine of the present invention to treat, and after 3 courses for the treatment of, patients symptomatic substantially alleviates. Continuing to take 3 courses for the treatment of, patient's focal symptom is wholly absent, and follows up a case by regular visits to 1 year without recurrence.
Case 2: Feng, man, 46 years old, chronic cough, hemoptysis, become thin, be lung bronchogenic carcinoma through hospital diagnosis, after taking 2 courses for the treatment of of medicine of the present invention, cough hemoptysis stops, and feed is normal, and the tired sense of health alleviates, and complexion recovers ruddy.
Case 3: side certain, man, 59 years old. Patient has the smoking history of more than ten years. Cough, sputum mixed with blood, the symptom such as chest pain occur in this year, checks and be diagnosed as pulmonary carcinoma. Through taking medicine of the present invention, after 4 courses for the treatment of, patients symptomatic substantially alleviates, and continues to take 3 courses for the treatment of, and patient's focal symptom is wholly absent, and follows up a case by regular visits to 1 year without recurrence.
Case 4: Wang, man, 52 years old. Patient is because of feeling of oppression and pain in the chest to hospital's CT examination: CT examination finds that there is 3.9 �� 4.6cm shade in pulmonary, diagnoses as pulmonary carcinoma. Through taking medicine of the present invention, after 3 courses for the treatment of, CT examination pulmonary shadow is reduced into 2.0 �� 2.3cm, takes 6 courses for the treatment of continuously, and CT examination pulmonary shadow disappears, and follows up a case by regular visits to survival so far.
Claims (4)
1. the medicine of Lung Cancer with Integrated Traditonal Chinese Westren Medicine, it is characterised in that be made up of the raw material of following weight portion: Flos Buddlejae 55-80 part, Caulis Erycibes 41-59 part, Herba Adenosmae 31-49 part, Fructus Malvae 22-43 part, Medulla Stachyuri (Medulla Helwingiae) 20-34 part, Stenoloma chusana 15-28 part, Radix Ardisiae Crenatae 10-18 part, BIBO 5-13 part, Radix Astragali Preparata 2-11 part, Iressa 0.1-0.6 part, gemcitabine 0.5-1.3 part, docetaxel 0.6-1.8 part.
2. medicine according to claim 1, it is characterised in that be made up of the raw material of Chinese medicine of following weight portion: Flos Buddlejae 63 parts, Caulis Erycibes 52 parts, Herba Adenosmae 40 parts, Fructus Malvae 32 parts, Medulla Stachyuri (Medulla Helwingiae) 26 parts, Stenoloma chusana 20 parts, Radix Ardisiae Crenatae 14 parts, BIBO 8 parts, Radix Astragali Preparata 5 parts, Iressa 0.3 part, gemcitabine 0.9 part, docetaxel 1.2 parts.
3. the method preparing medicine described in any of the above-described claim, it is characterised in that comprise the following steps:
(1) take Flos Buddlejae, Caulis Erycibes, Herba Adenosmae and Fructus Malvae and add distilled water immersion 5-9 hour, extract volatile oil with volatile oil extractor, dry acquirement volatile oil with anhydrous magnesium sulfate, then use hydroxypropyl��-cyclodextrin inclusion, preparing clathrate, clathrate and medicinal residues are standby;
(2) take Medulla Stachyuri (Medulla Helwingiae), Stenoloma chusana, Radix Ardisiae Crenatae, add 75% ethanol extraction 3-6 time, each 1-3 hour, merge medicinal liquid, stand 24 hours, standby;
(3) after taking the medicinal residues mixing of BIBO, Radix Astragali Preparata and step (1), then the ethanol adding the water of gross weight 5-6 times and the 70% of 0.3-1 times decocts 1.5-3h, double, merges the extracting solution of twice;
(4) taking the supernatant of step (2), (3), decompression recycling ethanol, be concentrated into 55 DEG C-65 DEG C, density is the extractum of 1.01-1.04, and concentrate drying makes powder;
(5) by the clathrate of step (1), the powder of (4) and Iressa, gemcitabine, docetaxel mix homogeneously.
4. method according to claim 3, it is characterised in that in step (1), the weight of distilled water is 3-6 times of Flos Buddlejae, Caulis Erycibes, Herba Adenosmae and Fructus Malvae gross weight, and temperature is 40-60 degree Celsius.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610170936.8A CN105641171A (en) | 2016-03-24 | 2016-03-24 | Medicine for treating lung cancer by combination of Chinese traditional medicine and western medicine and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610170936.8A CN105641171A (en) | 2016-03-24 | 2016-03-24 | Medicine for treating lung cancer by combination of Chinese traditional medicine and western medicine and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105641171A true CN105641171A (en) | 2016-06-08 |
Family
ID=56495474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610170936.8A Pending CN105641171A (en) | 2016-03-24 | 2016-03-24 | Medicine for treating lung cancer by combination of Chinese traditional medicine and western medicine and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105641171A (en) |
-
2016
- 2016-03-24 CN CN201610170936.8A patent/CN105641171A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102258563B (en) | Anti-cancer medicinal composition and Chinese medicinal composition | |
| CN101947284B (en) | Traditional Chinese medicinal composition for treating diabetes and preparation method thereof | |
| CN105943615A (en) | Application of whole hemp extract in preparation of pancreatic cancer treating drug | |
| CN104547496B (en) | A kind of Chinese medicine composition to moisten the lung and relieve the cough and preparation method thereof | |
| CN107281388A (en) | Compound dendrobium huoshanense preparation, concentration water-honeyed pill for health care and preparation method thereof | |
| CN107625828A (en) | A kind of health protection tea for auxiliary treatment chronic pharyngitis, preparation method and application | |
| CN104324316A (en) | Application of traditional Chinese medicine composition to prepare medicines treating colorectal cancer | |
| CN105687450A (en) | Medicament capable of treating lung cancer by virtue of combined treatment of traditional Chinese medicine and western medicine | |
| CN1730093A (en) | Chinese traditional medicine preparation for treating cancer and application thereof | |
| CN105641171A (en) | Medicine for treating lung cancer by combination of Chinese traditional medicine and western medicine and preparation method thereof | |
| TW201332563A (en) | Chinese herbal formulation for treating terminally ill cancer constipation and method thereof | |
| CN102091110B (en) | Chinese patent medicine capsule for treating lung cancer | |
| CN101020002B (en) | Compound Chinese medicine preparation for assisting tumor radiotherapy and its preparation method | |
| CN105726745A (en) | Medicine for treating lung cancers by combining traditional Chinese medicines and western medicines and preparation method thereof | |
| CN104524359B (en) | A kind of Chinese medicine composition, its preparation method and application | |
| CN103251751B (en) | Traditional Chinese medicine composition for treating primary dysmenorrheal and preparation method thereof | |
| CN102940674B (en) | Medicine composition for treating benign prostatic hyperplasia | |
| CN102000303B (en) | Compound traditional Chinese medicine preparation for suppressing tumors | |
| CN108143818A (en) | A kind of Chinese medicine composition for controlling cough and asthma | |
| CN105943579A (en) | Pharmaceutical composition for treating gastric cancer and preparation method of pharmaceutical composition | |
| CN105832949A (en) | Pharmaceutical preparation for metastatic bone pain of thyroid cancer | |
| CN105412673A (en) | Drug for treating Hashimoto disease and preparing method thereof | |
| CN104606377A (en) | Traditional Chinese medicinal composition for treating gastritis | |
| CN104352974A (en) | Ciliatenerve knotweed root-containing traditional Chinese medicine composition for treating diabetes | |
| CN110302247A (en) | A kind of pharmaceutical composition assisting in the treatment of prostate cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160608 |